- Home
- VATE vs SLGL Comparison
VATE vs SLGL Comparison
Compare VATE & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VATE | SLGL |
|---|---|---|
| Founded | 1994 | 1997 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 228.1M | 247.1M |
| IPO Year | 1996 | 2016 |
Fundamental Metrics
Financial Performance| Metric | VATE | SLGL |
|---|---|---|
| Price | $20.06 | $74.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $110.00 |
| AVG Volume (30 Days) | ★ 68.8K | 34.4K |
| Earning Date | 05-14-2026 | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,246,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $223.84 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 12.55 | N/A |
| 52 Week Low | $3.75 | $6.96 |
| 52 Week High | $21.30 | $97.97 |
Technical Indicators
Market Signals| Indicator | VATE | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 70.11 | 51.52 |
| Support Level | $4.48 | $65.48 |
| Resistance Level | N/A | $75.00 |
| Average True Range (ATR) | 1.72 | 5.34 |
| MACD | 0.09 | -0.20 |
| Stochastic Oscillator | 79.77 | 56.44 |
Price Performance
Historical ComparisonAbout VATE INNOVATE Corp.
Innovate Corp is a diversified holding company that has a portfolio of subsidiaries in a variety of operating segments. Its segments include Infrastructure, Life Sciences and Spectrum, and Other segment. Through its subsidiaries it provides fully integrated structural and steel construction services; supports healthcare and biotechnology product development; and operates Over-The-Air (OTA) broadcasting stations across the United States (U.S.) including Puerto Rico.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.